| abstract |
A pharmaceutical composition comprising, as activeningredient, N-4-(1H-tetrazol-5-yl)phenyl-4-(1H-tetrazol-5-yl)benzamidendisodium salt (CR 2039, Andolast) or anothernpharmaceutically-acceptable salt thereof and a flavouring, andnoptionally including a pharmaceutically-acceptable inertncarrier and/or a pharmaceutically-acceptable sweetener, thencomposition being suitable for administration by oralninhalation. |